Bicara Therapeutics FY Conference Summary Company Overview - **Company Name**: Bicara Therapeutics (NasdaqGM:BCAX) - **Industry**: Biotechnology, specifically focused on targeted tumor modulation - **Headquarters**: Boston, Massachusetts - **Employee Count**: Approximately 100 Core Product - **Lead Program**: Ficerafusp alfa - **Mechanism**: Bifunctional antibody targeting solid tumors, specifically designed to penetrate tumors and modulate the tumor microenvironment - **Indications**: Primarily focused on HPV-negative recurrent and metastatic head and neck cancer Key Highlights from 2025 - **Clinical Development**: Significant progress in the clinical development of ficerafusp alfa, with two important data sets showing: - Depth and durability of response - Meaningful overall survival benefits compared to standard care in HPV-negative head and neck cancer [6][14] - **FDA Breakthrough Designation**: Granted for the HPV-negative subtype, recognizing it as a distinct clinical subtype with limited treatment options [6][7] - **Pivotal Study Initiation**: Launched the FORTIFY-HNS study, a seamless phase II/III trial for potential accelerated approval of ficerafusp alfa plus Pembrolizumab (Pembro) [8][19] 2026 Corporate Outlook - **Key Focus Areas**: - Execute the strategic development plan for ficerafusp alfa in frontline HPV-negative recurrent and metastatic head and neck cancer [9] - Anticipate an early launch in early 2028, with a focus on building a commercial foundation [9][10] - Hire a Chief Commercial Officer to support commercial strategy [10] - **Market Potential**: The head and neck cancer market is projected to exceed $5 billion by 2030, with 50,000 annual incidence cases of HPV-negative recurrent and metastatic head and neck cancer [20][34] Clinical Data Insights - **Response Rates**: Ficerafusp alfa demonstrated a confirmed response rate of 54%, with 80% of responders achieving at least 80% tumor shrinkage [12] - **Durability of Response**: Median duration of response was reported at 21.7 months, significantly exceeding standard care [13] - **Overall Survival**: Median overall survival greater than 21 months, tripling the standard of care outcomes [14][15] Safety Profile - **Well-Tolerated**: Ficerafusp alfa has shown a favorable safety profile, designed to minimize TGF- related toxicities [16] Future Development Plans - **Expansion into Other Tumor Types**: Plans to explore ficerafusp alfa's potential in metastatic colorectal cancer and pancreatic cancer, leveraging preclinical data [23][24] - **Proof-of-Concept Studies**: Initiated cohorts for ficerafusp alfa monotherapy and combination therapy in third-line MSS RAS wild-type metastatic colorectal cancer [24] Financial Guidance - **Cash Runway**: Bicara has over $400 million to fund its pivotal study through its confirmatory endpoint [40] Conclusion - **Strategic Vision**: Bicara Therapeutics is positioned for significant growth in 2026, focusing on executing its pivotal study, building a commercial foundation, and expanding its pipeline beyond head and neck cancer [41]